Ibrutinib for chronic lymphocytic leukaemia in Italy: high discontinuation rates for costly therapy
Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Drugs & Pharmacology | Italy Health | Leukemia